You have free access to this content

Cancer

Cover image for Vol. 117 Issue 14

15 July 2011

Volume 117, Issue 14

Pages 3061–3286

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. You have free access to this content
    2. You have free access to this content
  2. Commentaries

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. You have free access to this content
      Preventing invasive breast cancer : Another benefit from mammographic screening (pages 3064–3068)

      Blake Cady and Maureen A. Chung

      Article first published online: 18 JAN 2011 | DOI: 10.1002/cncr.25764

      Invasive breast cancer incidence has decreased in the United States since 1998. Widespread excision of preinvasive ductal carcinoma in situ over many years may be a principal cause.

  3. Review Articles

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. You have free access to this content
      Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer (pages 3069–3080)

      Alice De Sanctis, Laurent Taillade, Stephane Vignot, Silvia Novello, Rosa Conforti, Jean Philippe Spano, Giorgio Vittorio Scagliotti and David Khayat

      Article first published online: 31 JAN 2011 | DOI: 10.1002/cncr.25894

      Standard chemotherapy and new targeted therapies that are used to treat nonsmall cell lung cancer have been responsible for a consistent number of cases of drug-induced pulmonary toxicity (DIPT) in patients whose respiratory function already may have been compromised by smoking-related diseases or by cancer itself. In this review, the authors investigated the possible DIPTs from different antineoplastic drugs to help clinicians in their diagnosis, which remains one of exclusion.

    2. You have free access to this content
      Diagnosis and management of dysplasia and cancer of the ileal pouch in patients with underlying inflammatory bowel disease (pages 3081–3092)

      Zhao-xiu Liu, Ravi P. Kiran, Ana E. Bennett, Run-zhou Ni and Bo Shen

      Article first published online: 24 JAN 2011 | DOI: 10.1002/cncr.25886

      Restorative proctocolectomy with ileal pouch-anal anastomosis does not abolish the risk of developing pouch neoplasia. Although the need and interval of surveillance endoscopy are controversial, the authors propose diagnostic and treatment algorithms.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. Disease Site

      Breast Disease
      You have free access to this content
      Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers (pages 3093–3100)

      Larissa J. Lee, Brian Alexander, Stuart J. Schnitt, Amy Comander, Bridget Gallagher, Judy E. Garber and Nadine Tung

      Article first published online: 24 JAN 2011 | DOI: 10.1002/cncr.25911

      The clinical outcome of 117 women with stage I to III triple negative breast cancer treated with conventional chemotherapy was analyzed with respect to BRCA1 mutation status. Survival, relapse rates, and the sites of distant metastasis were similar among BRCA1 mutation carriers and noncarriers.

    2. You have free access to this content
      Breast cancer screening beliefs, recommendations and practices : Primary care physicians in the united states (pages 3101–3111)

      Helen I. Meissner, Carrie N. Klabunde, Paul K. Han, Vicki B. Benard and Nancy Breen

      Article first published online: 18 JAN 2011 | DOI: 10.1002/cncr.25873

      To the authors' knowledge, this is the first national study in over 2 decades to report the breast cancer screening practices of primary care physicians and provides baseline data to monitor the impact of changes in clinical practice guidelines. The findings suggested that virtually all primary care physicians routinely recommended mammography, clinical breast examination and breast self-examination to their patients aged ≥ 40 years, although recommendations varied by primary care specialty.

    3. You have free access to this content
      Germline mutations of the E-cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer (pages 3112–3117)

      Ze Ming Xie, Lai Sheng Li, Claire Laquet, Frédérique Penault-Llorca, Nancy Uhrhammer, Xiao Ming Xie and Yves Jean Bignon

      Article first published online: 26 JAN 2011 | DOI: 10.1002/cncr.25876

      Germline CDH1 mutation can be cosegregated with inherited invasive lobular breast cancer (ILBC) in the absence of diffuse gastric cancer (DGC). Present data do not support recommendation of prophylactic gastrectomy in CDH1 germline mutation carriers with ILBC.

    4. Gastrointestinal Disease
      You have free access to this content
      Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer (pages 3118–3125)

      Matteo Frasson, Eduardo Garcia-Granero, Desamparados Roda, Blas Flor-Lorente, Susana Roselló, Pedro Esclapez, Carmen Faus, Samuel Navarro, Salvador Campos and Andrés Cervantes

      Article first published online: 24 JAN 2011 | DOI: 10.1002/cncr.25866

      The current data suggested that preoperative chemoradiotherapy may be unnecessary in patients who have clinical T3 (cT3) and cT2/lymph node-positive rectal cancer if the clinical circumferential resection margin is free and if no other adverse factors for local recurrence are present, thus avoiding the over treatment of a large number of patients. In consequence, the widely accepted practice of indicating neoadjuvant therapy for all patients who have cT3 or clinically lymph node-positive rectal cancer should be re-evaluated in large prospective trials.

    5. You have free access to this content
      Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer (pages 3126–3134)

      Richard Kim, Ann Tan, Kevin K. Lai, John Jiang, Yixen Wang, Lisa A. Rybicki and Xiulu Liu

      Article first published online: 24 JAN 2011 | DOI: 10.1002/cncr.25883

      To the authors' knowledge, this was the first study to look at both human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) as potential prognostic markers in resected pancreatic cancer. The study showed that expression of hENT-1 correlated with better outcome, but no prognostic value for RRM1 in resected pancreatic cancer was seen.

    6. You have free access to this content
      Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45 (pages 3135–3147)

      Hua Li, Yasushi Adachi, Hiroyuki Yamamoto, Yongfen Min, Hirokazu Ohashi, Masanori Ii, Yoshiaki Arimura, Takao Endo, Choon-Taek Lee, David P. Carbone, Kohzoh Imai and Yasuhisa Shinomura

      Article first published online: 24 JAN 2011 | DOI: 10.1002/cncr.25893

      The authors report that the inhibition of insulin-like growth factor-I receptor (IGF-IR) down-regulated vascular endothelial growth factor (VEGF) signaling in gastric cancer xenografts and inhibited both tumor angiogenesis and lymphangiogenesis, and the combination of IGF-IR inhibition and VEGF inhibition was dramatically more effective than the inhibition of either alone without evident toxicity. In this study, a novel interaction was identified between 2 validated therapeutic targets, suggesting that the combination of these therapies may be clinically synergistic in gastric cancer, and the authors believe that further investigation of the potential of this approach is warranted.

    7. You have free access to this content
      Association between mitochondrial DNA content in leukocytes and colorectal cancer risk : A case-control analysis (pages 3148–3155)

      Falin Qu, Xiaonan Liu, Feng Zhou, Hushan Yang, Guoqiang Bao, Xianli He and Jinliang Xing

      Article first published online: 18 JAN 2011 | DOI: 10.1002/cncr.25906

      New findings provide the first epidemiological evidence linking the high mitochondrial DNA content in peripheral blood lymphocytes to elevated colorectal cancer risk.

    8. You have free access to this content
      Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients (pages 3156–3162)

      Katerina Shulman, Ilana Cohen, Ofra Barnett-Griness, Abraham Kuten, Stephen B. Gruber, Flavio Lejbkowicz and Gad Rennert

      Article first published online: 1 FEB 2011 | DOI: 10.1002/cncr.25735

      The UGT1A1*28 7/7 genotype is strongly associated with severe toxicity and higher hospitalization rate and predicts lower survival of colorectal cancer in users of irinotecan. Genetic testing is recommended before initiation of treatment with irinotecan.

    9. Gynecologic Oncology
      You have free access to this content
      Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody (pages 3163–3172)

      Joyce Varughese, Emiliano Cocco, Stefania Bellone, Maria de Leon, Marta Bellone, Paola Todeschini, Peter E. Schwartz, Thomas J. Rutherford, Sergio Pecorelli and Alessandro D. Santin

      Article first published online: 18 JAN 2011 | DOI: 10.1002/cncr.25891

      The treatment of advanced/metastatic uterine serous papillary carcinoma (USPC) is challenging, and the options are very limited. hRS7 is a humanized monoclonal antibody targeting Trop-2. In this study, we demonstrate that Trop-2 is overexpressed in USPC and that hRS7 induces a high level of antibody-dependent cellular cytotoxicity (ADCC) against multiple primary USPC cell lines resistant to chemotherapy. Trop-2 may represent an attractive novel target for the treatment of patients harboring USPC refractory to standard treatment modalities.

    10. Head and Neck Disease
      You have free access to this content
      Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer (pages 3173–3181)

      Johnny Kao, Eric M. Genden, Chien-Ting Chen, Michael Rivera, Charles C. L. Tong, Kryztof Misiukiewicz, Vishal Gupta, Vivek Gurudutt, Marita Teng and Stuart H. Packer

      Article first published online: 18 JAN 2011 | DOI: 10.1002/cncr.25786

      Fourteen patients with recurrent head and neck cancer received treatment with erlotinib (150 mg daily), celecoxib (200 to 600 mg twice daily), and reirradiation. The results indicated that combined erlotinib (150 mg daily), celecoxib (400 mg twice daily), and reirradiation (60 to 70.4 grays) is a feasible and active regimen in recurrent head and neck cancer.

    11. Hematologic Malignancies
      You have free access to this content
      Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia (pages 3182–3186)

      Alessandra Ferrajoli, Michael J. Keating, Susan O'Brien, Jorge Cortes and Deborah A. Thomas

      Article first published online: 18 JAN 2011 | DOI: 10.1002/cncr.25853

      This trial assessed several parameters after immunotherapy with standard-dose rituximab in patients with asymptomatic early stage chronic lymphocytic leukemia. Early treatment with rituximab was well tolerated and safe.

    12. Hepatobiliary Disease
      You have free access to this content
      Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma (pages 3187–3192)

      Weijing Sun, Davendra Sohal, Daniel G. Haller, Kristine Mykulowycz, Mark Rosen, Michael C. Soulen, Millie Caparro, Ursina R. Teitelbaum, Bruce Giantonio, Peter J. O'Dwyer, Abraham Shaked, Rajender Reddy and Kim Olthoff

      Article first published online: 24 JAN 2011 | DOI: 10.1002/cncr.25889

      Anti-angiogenesis agents have shown effectiveness in treatment of hepatocellular carcinoma (HCC). The combination of bevacizumab, oxaliplatin, and capecitabine showed encouraging results in both effective and safe profiles in treatment of patients with advanced unresectable and untransplantable HCC, especially in those patients with suboptimal performance status and liver function.

    13. Lung Disease
      You have free access to this content
      Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer : Coexpression with vascular endothelial growth factor-A predicts poor survival (pages 3193–3200)

      Tom Donnem, Kenneth Lonvik, Katrine Eklo, Thomas Berg, Sveinung W. Sorbye, Khalid Al-Shibli, Samer Al-Saad, Sigve Andersen, Helge Stenvold, Roy M. Bremnes and Lill-Tove Busund

      Article first published online: 24 JAN 2011 | DOI: 10.1002/cncr.25907

      MicroRNA-126 is involved in angiogenesis and is a strong and independent prognostic factor in nonsmall cell lung cancer. The prognostic impact has been shown to be highly associated with histology and in patients with nodal metastasis.

    14. You have free access to this content
      DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma (pages 3201–3208)

      Ji-Youn Han, Kyong-Ah Yoon, Jae Hee Park, Young Joo Lee, Geon Kook Lee, Jong Hee Han, Sung Jin Yoon, Tak Yun, Heung Tae Kim and Jin Soo Lee

      Article first published online: 24 JAN 2011 | DOI: 10.1002/cncr.25863

      Among nonsmokers with lung adenocarcinoma, those who had the x-ray repair cross-complementing group 1 (XRCC1) arginine (Arg)/Arg codon 399 genotype, the ribonucleotide reductase M1 (RRM1) codon 2464 guanine-guanine genotype, and the excision repair cross-complementation group 1 (ERCC1) codon 8092 cytosine-adenine genotype benefited from gefitinib and had a favorable prognosis.

    15. You have free access to this content
      Epigenetic mechanisms for silencing glutathione S-transferase m2 expression by hypermethylated specificity protein 1 binding in lung cancer (pages 3209–3221)

      Sheau-Chung Tang, Ming-Fang Wu, Ruey-Hong Wong, Yu-Fan Liu, Lee-Chun Tang, Chien-Hung Lai, Chung-Ping Hsu and Jiunn-Liang Ko

      Article first published online: 18 JAN 2011 | DOI: 10.1002/cncr.25875

      The current findings provided evidence indicating that hypermethylation of CpG islands within the glutathione S-transferase M2 (GST-M2) proximal promoter is a major mechanism that mediates the silence of GST-M2 gene expression in lung cancer cell lines.

    16. Neuro-Oncology
      You have free access to this content
      The impact of symptom interference using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on prediction of recurrence in primary brain tumor patients (pages 3222–3228)

      Terri S. Armstrong, Elizabeth Vera-Bolanos, Ibrahima Gning, Alvina Acquaye, Mark R. Gilbert, Charles Cleeland and Tito Mendoza

      Article first published online: 24 JAN 2011 | DOI: 10.1002/cncr.25892

      Symptom interference is associated with tumor recurrence in primary brain tumor patients. Symptom interference is more predictive of recurrence than performance status, age, or extent of resection.

    17. Sarcoma
      You have free access to this content
      Local control comparison of adjuvant brachytherapy to intensity-modulated radiotherapy in primary high-grade sarcoma of the extremity (pages 3229–3234)

      Kaled M. Alektiar, Murray F. Brennan and Samuel Singer

      Article first published online: 24 JAN 2011 | DOI: 10.1002/cncr.25882

      Adult patients with high-grade primary nonmetastatic soft tissue sarcoma of the extremity were treated with limb-sparing surgery and adjuvant radiotherapy. Adjuvant intensity-modulated radiotherapy provided better local control than brachytherapy, in patients with primary high-grade extremity sarcoma.

    18. You have free access to this content
      Isolated limb perfusion for unresectable extremity sarcoma : Results of 2 single-institution phase 2 trials (pages 3235–3241)

      Curtis J. Wray, Robert S. Benjamin, Kelly K. Hunt, Janice N. Cormier, Merrick I. Ross and Barry W. Feig

      Article first published online: 18 JAN 2011 | DOI: 10.1002/cncr.25850

      Limb perfusion for unresectable extremity sarcoma remains a treatment option. Results from the United States have not shown the same benefit as studies from Europe.

    19. Discipline

      Disparities Research
      You have free access to this content
      Effects of individual-level socioeconomic factors on racial disparities in cancer treatment and survival : Findings from the National Longitudinal Mortality Study, 1979-2003 (pages 3242–3251)

      Xianglin L. Du, Charles C. Lin, Norman J. Johnson and Sean Altekruse

      Article first published online: 24 JAN 2011 | DOI: 10.1002/cncr.25854

      Favorable survival was associated with higher socioeconomic status. Racial disparities in survival persisted after adjusting for individual-level socioeconomic factors and treatment for patients with breast and prostate cancer.

    20. You have free access to this content
      Comorbidities and mammography use interact to explain racial/ethnic disparities in breast cancer stage at diagnosis (pages 3252–3261)

      Shagufta Yasmeen, Guibo Xing, Cyllene Morris, Rowan T. Chlebowski and Patrick S. Romano

      Article first published online: 18 JAN 2011 | DOI: 10.1002/cncr.25857

      Comorbidity burden was associated with regular mammography and earlier stage at diagnosis, but the former association did not explain the latter. Racial/ethnic disparities in late-stage disease were reduced among women who received both regular mammograms and comorbidity-related care.

    21. Pediatric Oncology
      You have free access to this content
      Histology predicts a favorable outcome in young children with desmoplastic medulloblastoma : A report from the children's oncology group (pages 3262–3267)

      Sarah E.S. Leary, Tianni Zhou, Emiko Holmes, J. Russel Geyer and Douglas C. Miller

      Article first published online: 18 JAN 2011 | DOI: 10.1002/cncr.25856

      Children with desmoplastic medulloblastoma treated with chemotherapy alone experienced a favorable outcome compared with other histologic subtypes of medulloblastoma on the CCG-9921 trial. This finding supported the use of histologic subtype to identify patients for whom radiation therapy may be successfully eliminated.

    22. Symptom Control and Palliative Care
      You have free access to this content
      Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia (pages 3268–3275)

      Alessandra Ferrajoli, Aman U. Buzdar, Yvette DeJesus, Lee Cheng, Laura B. Michaud and Maria A. Rodriguez

      Article first published online: 24 JAN 2011 | DOI: 10.1002/cncr.25865

      We summarize our experience with erythropoiesis-stimulating agents in a tertiary oncology center and implementation of patient management tools for anemia.

    23. Translational Research
      You have free access to this content
      Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials (pages 3276–3283)

      Raoul Tibes, Barbara F. Piper, Jessica A. Smith, Raysenia L. James, Martin A. Benjamin, Jay H. Yim, Ramesh K. Ramanathan, Daniel D. Von Hoff, R. Curtis Bay and Mitesh J. Borad

      Article first published online: 18 JAN 2011 | DOI: 10.1002/cncr.25885

      Findings from this study have provided the first prospectively collected patient dataset on patients' willingness to undergo pharmacodynamic tests on early phase oncology trials. The results may be useful for informing the design of biomarker-driven trials in oncology.

  5. Correspondence

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. You have free access to this content
      Receptive anal intercourse as a potential risk factor for rectal cancer (page 3284)

      John J. Potterat, Devon D. Brewer and Stuart Brody

      Article first published online: 18 JAN 2011 | DOI: 10.1002/cncr.25909

    2. You have free access to this content
  6. Erratum

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. You have free access to this content
      Correction (page 3286)

      Article first published online: 26 APR 2011 | DOI: 10.1002/cncr.26158

      This article corrects:

      Modeling the mortality reduction due to computed tomography screening for lung cancer

      Vol. 117, Issue 12, 2703–2708, Article first published online: 10 JAN 2011

SEARCH

SEARCH BY CITATION